SCHEMBL277695

SCHEMBL277695

Oc1ccc2ccncc2n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 1/20 0.42
MINK1 Q8N4C8 1/20 0.42
TNIK Q9UKE5 1/20 0.42
MAPK10 P53779 2/20 0.37
KDM4E B2RXH2 1/20 0.36
MAPKAPK2 P49137 1/20 0.36
DAO P14920 1/20 0.35
ERN1 O75460 1/20 0.35
PDGFRB P09619 1/20 0.34
PDGFRA P16234 1/20 0.34
CDC7 O00311 1/20 0.34
PDE10A Q9Y233 1/20 0.33
PRKCZ Q05513 1/20 0.33
MELK Q14680 1/20 0.33
RPS6KA3 P51812 1/20 0.33
MAPT P10636 3/20 0.33
CASP1 P29466 2/20 0.33
NPC1 O15118 1/20 0.33
TP53 P04637 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL276051 0.82 KDM4E (0.41) MAPK10KDM4EMAPKAPK2DAOERN1
SCHEMBL31269699 0.76 MAP4K4 (0.58) MAP4K4MINK1TNIKMAPK10CDC7
SCHEMBL10615118 0.73 BACE1 (0.52) MAP4K4MINK1TNIKPRKCZCLK1
SCHEMBL277694 0.73 MAP4K4 (0.42) MAP4K4MINK1TNIKMAPK10DAO
SCHEMBL3816083 0.73 MAP4K4 (0.42) MAP4K4MINK1TNIKMAPK10KDM4E
SCHEMBL23674958 0.73 MAP4K4 (0.42) MAP4K4MINK1TNIKMAPK10PDE10A
SCHEMBL2005112 0.73 MAP4K4 (0.42) MAP4K4MINK1TNIKMAPK10PDE10A
SCHEMBL7513190 0.73 CYP1A2 (0.52) MAP4K4MINK1TNIKKDM4EPDE10A
SCHEMBL2265306 0.73 MAP4K4 (0.54) MAP4K4MINK1TNIKMAPK10PDE10A
SCHEMBL13911043 0.73 MAP4K4 (0.54) MAP4K4MINK1TNIKMAPK10CDC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106146491-A 5-hydroxyl-1,7-naphthyridine compounds, its preparation method and the pharmaceutical applications thereof being optionally substituted aryl or heteroaryl 沈阳三生制药有限责任公司 2016-11-23 CN disclosed
CN-106146490-A 5-hydroxyl-1,7-naphthyridine compounds, its preparation method and the pharmaceutical applications thereof replaced by aryloxy group or heteroaryloxy 沈阳三生制药有限责任公司 2016-11-23 CN disclosed
US-9174992-B2 Heterobicyclic compounds AMGEN INC. (US) 2015-11-03 US disclosed
US-9174992-B2 Heterobicyclic compounds AMGEN INC. (US) 2015-11-03 US disclosed
US-9115341-B2 Method for expanding hematopoietic stem cells using heterocyclic compound NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2015-08-25 US disclosed
EP-1636192-B9 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL IND LTD (JP) 2015-07-01 EP disclosed
US-20140051857-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2014-02-20 US disclosed
EP-1636192-B1 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL IND LTD (JP) 2014-01-15 EP disclosed
US-8552031-B2 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2013-10-08 US disclosed
WO-2013130890-A1 HETEROBICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS AMGEN INC. (US) 2013-09-06 WO disclosed
EP-0872903-B1 Method for making hydrogen storage alloy powder and electrode comprising the alloy powder SHINETSU CHEMICAL CO (JP) 2001-10-04 EP disclosed
US-6277519-B1 QUENCHING AN ALLOY MELT; COMMINUTION SHIN-ETSU CHEMICAL CO., LTD. (JP) 2001-08-21 US disclosed
EP-1072614-A1 Method for polymerizing vinyl monomers in a coated reactor SHIN-ETSU CHEMICAL CO., LTD. (JP) 2001-01-31 EP disclosed
EP-1063242-A1 Process for producing a polymer by polymerization of a monomer having an ethylenic double bond SHIN-ETSU CHEMICAL CO., LTD. (JP) 2000-12-27 EP disclosed
EP-1043338-A1 Polymerisation process in a reactor with double coating against scale formation SHIN-ETSU CHEMICAL CO., LTD. (JP) 2000-10-11 EP disclosed
US-6096144-A TREATING WITH ACIDIC OR ALKALINE SOLUTION OF CONJUGATED UNSATURATED COMPOUND WITH AT LEAST 5 BONDS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2000-08-01 US disclosed
US-5858571-A TREATING A PULVERIZED HYDROGEN ABSORBING ALLOY WITH A SOLUTION COMPRISING A CONJUGATED UNSATURATED COMPOUND SHIN-ETSU CHEMICAL CO., LTD. (JP) 1999-01-12 US disclosed
EP-0872903-A1 Method for making hydrogen storage alloy powder and electrode comprising the alloy powder Shin-Etsu Chemical Co., Ltd. (JP) 1998-10-21 EP disclosed
EP-0172427-B1 PROCESS FOR PRODUCTION OF VINYL CHLORIDE POLYMER Shin-Etsu Chemical Co., Ltd. (JP) 1989-07-05 EP disclosed
US-4757124-A Suspension or emulsion polymerizing vinyl chloride monomer or mixture of vinyl chloride with vinyl monomer copolymerizable therewith in reactor with walls coated with antiscaling compound containing dye or pigments SHIN-ETSU CHEMICAL CO., LTD. (JP) 1988-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051857-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NR2C2, ROR1, NR0B2 MAP4K4 1963/4885MINK1 4561/4885TNIK 4137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.